KRAS and cancer: Despite this, recent genomic analyses of NSCLC have identified increased mutation burden in brain metastases compared to primary tumors, particularly in genes such as CDKN2, TP53, KRAS, and EGFR50, a finding consistent with pan-cancer whole-genome analysis 47.